Harmony Biosciences (HRMY) Q3 2026 Earnings Call Transcript

Harmony Biosciences reported Q3 2026 net revenue of $268.9 million, up 12% year over year, and reiterated WAKIX full-year revenue guidance of $1.00 billion-$1.04 billion; average patients reached 9,350, up 400 from the prior period. Net income fell to $48.2 million from $50.9 million and diluted EPS to $0.81 from $0.87, reflecting higher royalty and milestone costs. Preliminary BP-205 Phase 1 data showed a mean effective half-life of approximately 29 hours, while the company expects a ruling in its AET ANDA litigation around February 2027 and said CEO Jeffrey Dayno will be succeeded by Peter Anastasiou on Jan. 1, 2027.

Analysis

HRMY’s near-term equity debate is less about the reported growth rate than whether patient additions can compound after added field and reimbursement support—and whether that growth converts to earnings. The new Novitium royalty is a structural gross-margin headwind, while the milestone charge is less clearly recurring; investors should separate those effects rather than extrapolate this quarter’s EPS decline mechanically. Verify subsequent cost-of-product-sold guidance and patient-add trends before underwriting operating leverage.

The February 2027 patent decision and preliminary-injunction process create an asymmetric event risk: an adverse outcome could pull generic-entry risk forward and pressure HRMY’s franchise value well before the company’s stated 2030 exclusivity horizon. Sandoz Group (SDZ), named as AET’s marketing partner in the amorphous-form litigation, has conditional exposure to that outcome, but the transcript does not establish the economics or likelihood of a launch. Management’s confidence is not independent evidence of the court’s ruling.

BP-205’s healthy-volunteer tolerability and PK are development-enabling, not efficacy proof. The Q1 2027 sleep-deprived-volunteer readout is the first meaningful efficacy check; phase II plans in mid-2027 leave a long gap before commercial value. Orexin competition, including Alkermes (ALKS), makes differentiation on usable efficacy and tolerability—not potency claims alone—the eventual valuation driver. The CEO handoff appears planned, but execution and capital discipline on business development remain untested. Overall, fundamentals are constructive, but litigation and clinical optionality argue against treating the pipeline as near-term earnings.

Key Decisions for Investors

• HRMY: Prefer a staged, catalyst-aware position over chasing the earnings narrative. Add only if prescription demand remains firm and the stock’s valuation adequately discounts the February 2027 litigation risk; no valuation data here supports a price target.
• Track the January 26, 2027 preliminary-injunction hearing and February ruling as separate catalysts. Reassess sharply on the court’s reasoning and any launch restrictions; a denial or adverse patent ruling would falsify the assumption that generic entry is contained through the stated exclusivity period.
• For the 1–3 month WAKIX thesis, monitor patient additions, prescription-fill timing and cost of sales. If patient growth weakens while royalty burden persists, the revenue-growth-to-EPS conversion case deteriorates even if full-year revenue guidance is met.
• Treat BP-205 as a watch item, not a basis for near-term earnings estimates. Reassess after the Q1 2027 volunteer efficacy data for dose-response, duration of wakefulness and tolerability; failure to show a usable efficacy/tolerability window would undermine the differentiation thesis versus ALKS and other orexin programs.
• SDZ is a litigation watch rather than a standalone short: the transcript gives no quantified exposure or probability of an at-risk launch. Verify court filings and the financial relevance to Sandoz before positioning.